 The purpose of this clinical experience study is to determine whether CC-5013 is safe and effective to include studying the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body pharmacokinetics in Japanese subjects with low- or intermediate-1-risk MDS IPSS risk categories associated with a deletion 5q31-33 abnormality and symptomatic anemia. 